NEW YORK (Reuters) – Pfizer Inc said on Thursday it will provide up to six million courses of antiviral treatment for COVID-19 to the Global Fund for NGOs for low- and middle-income countries seeking to address global disparities in response to the coronavirus.
The company said Paxlovid treatment courses will be available for purchase through the Global Fund’s COVID-19 Response Mechanism to 132 low- and middle-income countries this year, subject to local regulatory approvals.
While Paxlovid is widely available in many rich countries, its availability has been severely restricted in poor countries. Pfizer said the supply agreement is part of its strategy to facilitate equitable access to oral COVID treatments.
The company struck a deal with several generic drug makers to produce its treatment at a lower price for developing countries.
“This agreement with the Global Fund is a critical step that will advance equitable access to high-risk patients in low- and middle-income countries,” CEO Albert Burla said in a statement.
The global fund is part of the Access to COVID-19 Accelerator Partnership (ACT-A), an effort by governments and NGOs including the World Health Organization to procure tests, treatments and vaccines for low-income countries.